Last reviewed · How we verify
Inhaled Reduced Glutathione
Inhaled reduced glutathione acts as an antioxidant and mucolytic agent that replenishes intracellular glutathione levels and reduces oxidative stress in the lungs.
Inhaled reduced glutathione acts as an antioxidant and mucolytic agent that replenishes intracellular glutathione levels and reduces oxidative stress in the lungs. Used for Cystic fibrosis (likely primary indication), Idiopathic pulmonary fibrosis or other chronic lung diseases with oxidative stress.
At a glance
| Generic name | Inhaled Reduced Glutathione |
|---|---|
| Also known as | GSH |
| Sponsor | Serafino A. Marsico |
| Drug class | Antioxidant / Mucolytic agent |
| Target | Glutathione (endogenous antioxidant system) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonary |
| Phase | Phase 3 |
Mechanism of action
Glutathione is a tripeptide antioxidant that plays a critical role in protecting cells from oxidative damage and maintaining redox balance. When inhaled directly, reduced glutathione can increase local glutathione concentrations in respiratory epithelial cells and airway secretions, enhancing antioxidant defenses and potentially improving mucociliary clearance. This mechanism may be particularly beneficial in conditions characterized by oxidative stress and impaired lung function.
Approved indications
- Cystic fibrosis (likely primary indication)
- Idiopathic pulmonary fibrosis or other chronic lung diseases with oxidative stress
Common side effects
- Cough
- Bronchospasm
- Throat irritation
- Nausea
Key clinical trials
- Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant (PHASE3)
- Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough (PHASE2)
- A Breathing-Based Meditation Intervention for Patients With Treatment Resistant Late Life Depression (PHASE1)
- Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients (PHASE2)
- Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis (PHASE3)
- Effect of Hyperbaric Therapy on Markers of Oxidative Stress in Children With Autism (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inhaled Reduced Glutathione CI brief — competitive landscape report
- Inhaled Reduced Glutathione updates RSS · CI watch RSS
- Serafino A. Marsico portfolio CI